Laleh Amiri-Kordestani

36PUBLICATIONS
180CO-AUTHORS
Molecular targetsFood safety, traceability, certification and authenticityCancer therapy (excl. chemotherapy and radiation therapy)Medical biotechnology not elsewhere classifiedFood properties (incl. characteristics and health benefits)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (36)

|Aug 12, 2026
FDA Approval Summary: Erdafitinib for FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma.

|Jun 15, 2026
Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association.

|Mar 30, 2026
Is Progression-Free Survival 2 Ready for Prime Time in US Food and Drug Administration Regulatory Decision Making?

Mallorie H Fiero, Mirat Shah, Laleh Amiri-Kordestani

|Feb 12, 2026
FDA Approval Summary: Durvalumab for the Treatment of Adult Patients with Muscle-Invasive Bladder Cancer.

Nooshin Mirkheshti, Daniel Edem Kpormegbey, Chana Weinstock

|Oct 31, 2025
Reply to: Decoding the End Points of Poly (ADP-ribose) Polymerase Inhibitor Trials in Ovarian Cancer.

Mirat Shah, Mallorie H Fiero, Joyce Cheng

|Aug 27, 2025
FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer.

Melanie Royce, Mirat Shah, Lijun Zhang

Pageof 6

Frequent Collaborators

28 joint publications

Richard Pazdur

22 joint publications

Shenghui Tang

21 joint publications

William Pierce

12 joint publications

Xin Gao